Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 10470-83-4 | MDL No. : | MFCD04038780 |
Formula : | C9H5NO2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | NVJSPQCVDHGYRE-UHFFFAOYSA-N |
M.W : | 159.14 | Pubchem ID : | 388306 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 42.04 |
TPSA : | 47.03 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.77 cm/s |
Log Po/w (iLOGP) : | 0.87 |
Log Po/w (XLOGP3) : | 0.71 |
Log Po/w (WLOGP) : | 1.02 |
Log Po/w (MLOGP) : | -0.27 |
Log Po/w (SILICOS-IT) : | 1.76 |
Consensus Log Po/w : | 0.82 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.64 |
Solubility : | 3.61 mg/ml ; 0.0227 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.28 |
Solubility : | 8.44 mg/ml ; 0.053 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.43 |
Solubility : | 0.59 mg/ml ; 0.00371 mol/l |
Class : | Soluble |
PAINS : | 1.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.29 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P301+P312-P302+P352-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H320-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
82% | With [bis(acetoxy)iodo]benzene In water; acetonitrile at 0℃; for 1 h; Inert atmosphere | A solution of iodobenzene diacetate (10.35mmol, 3.3g) in 12mL CH3CN: H2O (2:1) was added to quinolin-5-ol (3) (3.45mmol, 0.50g) at 0°C under N2 and stirred for 1h. After the reaction was completed, water (40mL) was added, and the solution was extracted with EtOAc (3×20mL). The organic phase was washed by brine and concentrated in vacuo to give 4 as a yellow solid, yield 82percent. MS (ESI) m/z = 160 [M+H]+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
61% | With sodium dichromate; sulfuric acid In dichloromethane; water at 0℃; for 1 h; | To 0.80g (5.0mmol) of 5-amino-8-hydroxyquinoline in 150mL of CH2Cl2 at 0°C was added 150mL of a 5percent aqueous solution of H2SO4 followed by slow addition of a pre-cooled solution of 2.98g (10.0mmol) of sodium dichromate in 50mL of H2O at 0°C. The yellow solution became orange and biphasic. After 1h, the reaction was extracted with methylene chloride and washed with brine. The organic extract was dried over magnesium sulfate and filtered. The solvent was removed under reduced pressure to give a yellow solid. The solid was purified using silica gel column chromatography eluting 3:2 ethyl acetate–hexanes to afford 0.49g (61percent) of quinoline-5,8-dione. 1H NMR (400MHz, CDCl3) δ: 8.90 (d, J=4.6Hz, 1H), 8.71 (s, 1H), 8.41 (d, J=8.1Hz, 1H), 7.74 (dd, J=4.6, 8.1Hz, 1H), 7.06 (d, J=10.9Hz, 1H), 6.90 (d, J=10.9Hz, 1H). 13C NMR (100.17MHz, CDCl3) δ: 182.1, 180.7, 148.8, 147.2, 138.2, 138.1, 135.4, 129.0, 128.3. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
44% | With potassium dihydrogenphosphate; Fremy's salt In water; acetone at 20℃; for 3.16667 h; | Example 2.1: Procedure for the Preparation of the Starting Materials; Typically a solution of Fremy's salt (1 g, 4 mmol) and potassium dihydrogenphosphate (400 mg, 3 mmol) in water (75 ml) was stirred at room temperature for 10 min then the quinolinol (6 mmol) in acetone (70 ml) was added. The mixture was stirred for 30 min, then a further solution of Fremy's salt (1 g) and potassium dihydrogenphosphate (400 mg) in water (30 ml) was added and the mixture stirred for 30 min, then a further solution of Fremy's salt (1 g) and potassium dihydrogenphosphate (400 mg) in water (30 ml) was added and the mixture stirred for a further 2 h. The mixture was extracted into dichloromethane, dried and evaporated in vacuo to give the product as an orange gum. Purification by column chromatography over silica gel eluting with ethyl acetate (0 - 40percent ) in dichloromethane gave the products as orange solids.The following quinolines were prepared using this method; 5,8-Dihydro-5,8-dioxoquinoline (reg. no. 858471-89-3); 8-Hydroxyquinoline (1 g, 7 mmol) to give quinone (0.48 g, 44percent). |
[ 56826-69-8 ]
6,7-Dihydro-5H-quinoline-8-one
Similarity: 0.84
[ 6541-19-1 ]
6,7-Dichloroquinoline-5,8-dione
Similarity: 0.75
[ 6541-19-1 ]
6,7-Dichloroquinoline-5,8-dione
Similarity: 0.75
[ 108166-03-6 ]
2-Methylquinoline-6-carbaldehyde
Similarity: 0.69